Teva Pharma (NYSE: TEVA) shares sink nearly 16% in pre-open trade following weak results and outlook.

Earnings Momentum Movers Trader Talk

Credit Suisse Downgrades Teva Pharma (TEVA) to NeutralAugust 4, 2017 6:01 AM RBC Capital Double Downgrades Teva Pharma (TEVA) to UnderperformAugust 4, 2017 5:54 AM Cowen Downgrades Teva Pharma (TEVA) to Market PerformAugust 4, 2017 5:51 AM Teva Pharma (TEVA) Cracks Fresh Low, Now Down 19.65%August 3, 2017 11:17 AM Mylan (MYL) Sinks Following Teva Results, OutlookAugust 3, 2017 8:13 AM Teva Pharma (TEVA) Lowers Quarterly Dividend 75% to $0.085; 1.1% YieldAugust 3, 2017 6:35 AM Teva Pharma (TEVA) Misses Q2 EPS by 4c, Lowers FY EPS Guidance, Cuts DividendAugust 3, 2017 6:33 AM